Korean Circ J.  1988 Sep;18(3):431-439. 10.4070/kcj.1988.18.3.431.

A Clinical Study on the Antihypertensive Effect of Enalapril

• Son JH
• Jung SS
• Choi YC
• Kim JH
• Lim HK
• Lee BH
• Lee CK

• KMID: 1938174
• DOI: http://doi.org/10.4070/kcj.1988.18.3.431

Abstract

Enalapril, a new angiotensin converting enzyme inhibitor,was administered in 30 hypertensive patients for 12 weeks or longer in order to evaluate the antihypertensive effects and side effects (in some cases combination with hydrochlorthiazide). The doses were from 10mg to 40mg once a day. The results were as follows : 1) Before medication and 2, 4, 6, 8, 10 and 12weeks of medication, the average systolic and diastolic pressure were 176.7+/-16.0/108.6+/-7.6, 146.0+/-12.5/91.7+/-6.9, 138.3+/-16.1/87.3+/-10.6, 140.7+/-13.9/87.3+/-9.6, 137.3+/-13.5/87.7+/-9.1, 137.3+/-14.8/87.0+/-8.5, 138.7+/-15.4/87.3+/-9.1mmHg respectively. After 12 weeks of medication, marked or moderate degree of anti-hypertensive effect was observed in 90% of all cases (p<0.005), and the further significant decease of systolic blood pressure after 4 weeks compared with 2 weeks (p<0.025) was observed. 2) There was no significant change in pulse rate before and after medication. 3) There was no significant change in the laboratory findings such as fasting blood sugar, serum BUN, creatinine, cholesterol, GOT, GPT, blood WBC, hemoglobin, hematocrit, and urine protein before and after treatment. 4) The side effects of enalapril were observed in 2 cases of 30 cases (6.6%), mild dizziness and mild fatigue, which were not required discontinuing the medication or decreasing the dose.

MeSH Terms

Blood Glucose
Blood Pressure
Cholesterol
Creatinine
Dizziness
Enalapril*
Fasting
Fatigue
Heart Rate
Hematocrit
Humans
Peptidyl-Dipeptidase A
Blood Glucose
Cholesterol
Creatinine
Enalapril
Peptidyl-Dipeptidase A